PMID: 16619518Apr 20, 2006Paper

Is aneusomy of chromosome 9 alone a valid biomarker for urinary bladder cancer screening?

Anticancer Research
Anna D PananiCharis Roussos

Abstract

Detection of genetically-changed tumor cells in the urine is one of the new approaches for the screening of bladder carcinomas. In a previous study, numerical aberrations of chromosome 9 were found in 85.18% of bladder tumors studied by the fluorescence in situ hybridization (FISH) technique. The purpose of the present study was to investigate whether chromosome 9 aneusomy alone is a valid, cost effective, biomarker for bladder cancer screening. Twenty-seven voided urine specimens obtained from 22 bladder cancer patients, either at initial diagnosis or at the follow-up, were analyzed by the FISH technique with the centromeric probe specific for chromosome 9. In all except 2 out of the 13 specimens with a histological confirmation of cancer, FISH analysis showed aneusomy 9 (sensitivity 84.61%). Among 6 cases with a negative cystoscopy but a positive FISH analysis, 3 recurred within the following 2 months, while 2 no-recurrent patients continued to show positive FISH findings after 6 months. One patient was considered to be false-positive. Four cases with a negative cystoscopy showed disomy 9 and 2 of them recurred. Aneusomy 9 has a high sensitivity (84.61%) for the detection of bladder cancer. Patients with a negative cystoscopy...Continue Reading

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.